PharmaCyte Biotech (PMCB) Accumulated Expenses (2011 - 2026)
PharmaCyte Biotech (PMCB) posted quarterly Accumulated Expenses of $522831.0 for Q2 2026, down 79.42% year-over-year from $2.5 million in Q2 2025, and up 17.32% quarter-over-quarter from $445656.0 in Q1 2026.
PharmaCyte Biotech (PMCB) Accumulated Expenses (2011 - 2026) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported Accumulated Expenses for 16 consecutive years, with $522831.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Accumulated Expenses fell 79.42% year-over-year to $522831.0; the TTM figure through Apr 2026 stood at $522831.0 (down 79.42% YoY), while the FY2026 annual figure was $522831.0, down 79.42% from the prior year.
- Accumulated Expenses rose to $522831.0 in Q2 2026 per PMCB's latest filing, from $445656.0 in the prior quarter.
- Across five years, Accumulated Expenses topped out at $2.5 million in Q2 2025 and bottomed at $381899.0 in Q1 2023.
- Historically, Accumulated Expenses has averaged $698498.6 across 5 years, with a median of $526581.0 in 2022.
- Annual changes were most pronounced in 2022 — Accumulated Expenses soared 1446.8% — and 2026, when it slumped 79.42%.
- PharmaCyte Biotech's Accumulated Expenses stood at $449855.0 in 2022, then soared by 126.33% to $1.0 million in 2023, then slumped by 30.54% to $707185.0 in 2024, then retreated by 26.38% to $520656.0 in 2025, then gained by 0.42% to $522831.0 in 2026.
- Business Quant data shows PMCB's Accumulated Expenses at $522831.0 in Q2 2026, $445656.0 in Q1 2026, and $520656.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | PharmaCyte Biotech | 4.38 Mn | 4.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 522,831.00 |
| Jan 31, 2026 | 445,656.00 |
| Oct 31, 2025 | 520,656.00 |
| Jul 31, 2025 | 595,656.00 |
| Apr 30, 2025 | 2.54 Mn |
| Jan 31, 2025 | 709,436.00 |
| Oct 31, 2024 | 707,185.00 |
| Jul 31, 2024 | 684,136.00 |
| Apr 30, 2024 | 735,199.00 |
| Jan 31, 2024 | 774,439.00 |
| Oct 31, 2023 | 1.02 Mn |
| Jul 31, 2023 | 480,036.00 |
| Apr 30, 2023 | 458,300.00 |
| Jan 31, 2023 | 381,899.00 |
| Oct 31, 2022 | 449,855.00 |
| Jul 31, 2022 | 530,331.00 |
| Apr 30, 2022 | 499,009.00 |
| Jan 31, 2022 | 520,115.00 |
| Oct 31, 2021 | 29,083.00 |
| Jul 31, 2021 | 530,199.00 |